Major Pharma Investments Flood America—Trump’s Tariffs Force Industry’s Hand
In a historic week for American manufacturing, global pharmaceutical titans Roche and Regeneron have unveiled multi-billion-dollar investments in U.S. facilities, moves widely recognized as direct responses to President Donald Trump’s America First trade and tariff policies. Reuters reports that Swiss giant Roche will invest a staggering $50 billion over the next five years, creating more than 12,000 new jobs. Meanwhile, Regeneron has inked a $3 billion deal with Fujifilm Diosynth to nearly double its U.S. manufacturing capacity.
These announcements come as the Trump administration prepares to roll out major tariffs on imported pharmaceuticals, a move designed to end decades of offshoring and bring critical medicine production back to American soil. As President Trump declared at a recent National Republican Congressional Committee dinner, “We will be revealing a substantial tariff on pharmaceuticals very soon.” CNBC
Roche and Regeneron: Billions Invested, Thousands of Jobs Created
Roche’s $50 billion commitment will fund new manufacturing plants, R&D centers, and a state-of-the-art gene therapy facility, with over 6,500 construction jobs and 1,000 positions at new or expanded sites. Once operational, Roche will export more medicines from the U.S. than it imports, reversing the decades-long trend of American dependency on foreign drugmakers. CEO Thomas Schinecker emphasized, “Our $50 billion investment over the next five years will establish the groundwork for our next phase of innovation, benefiting patients in the U.S. and globally.” Reuters
Regeneron’s $3 billion partnership with Fujifilm Diosynth will nearly double its domestic production, leveraging a new facility in North Carolina and expanding its Tarrytown, New York campus. Regeneron has already added 7,000 U.S. jobs in the past five years and is planning at least 1,000 more. Fierce Pharma
“Our ongoing and future investments in both New York and North Carolina are projected to surpass $7 billion, helping support high-paying jobs in the region.” — Regeneron press release, April 22, 2025
Trump’s America First Policies: The Real Catalyst
Mainstream media and industry insiders have tried to downplay these investments as mere business decisions, but the facts are clear: Trump’s America First tariffs and trade agenda are forcing Big Pharma to bring manufacturing home. The administration’s threat of sector-specific tariffs—up to 31% on Swiss imports and a possible 25% on all pharmaceutical imports—has left companies with no choice but to invest in U.S. facilities or face crippling costs. Yahoo News
The America First Trade Policy memorandum, signed January 20, 2025, lays out a comprehensive strategy to reclaim American manufacturing, protect national security, and reverse economic decline. Trump’s approach has already delivered results: from 2016 to 2019, real median household incomes grew by 10.5%—over ten times the rate of the previous sixteen years.
Exposing the Alternative Narrative: Media Doubt vs. Economic Reality
Critics claim Trump’s tariffs will stifle innovation or raise drug prices. But the evidence tells a different story. During Trump’s first term, the FDA approved record numbers of generic drugs, leading to a 2.4% annual price decrease in 2019—the largest in nearly 50 years. America First Policy Institute
Industry leaders have warned of “trade-offs” and possible R&D cuts, but their actions reveal the truth: faced with tariffs, they are choosing to invest in America, create jobs, and strengthen the domestic supply chain. As BioSpace notes, “Regeneron and Roche are the two latest Big Pharma players that have responded to Trump’s tariff threats,” joining Eli Lilly, Johnson & Johnson, Novartis, and AstraZeneca in announcing tens of billions in new U.S. investments.
America’s Future: Secure Medicines, Strong Jobs, and a Revitalized Economy
By putting America First, President Trump is delivering on his promise to revitalize American manufacturing, secure critical medicine supplies, and create high-quality jobs for American workers. The pharmaceutical sector’s massive investments are just the latest proof that strong leadership and tough trade policies work.
Stay informed and engaged as we continue to expose the truth, drain the swamp, and reclaim America’s economic destiny. Follow Golden Age Patriots on X and Facebook for more updates on the fight to put America first.
